Dos Santos Medeiros Sandrelli Meridiana de Fátima Ramos, Sousa Lino Bruna Maria Nepomuceno, Perez Vinícius Pietta, Sousa Eduardo Sérgio Soares, Campana Eloiza Helena, Miyajima Fábio, Carvalho-Silva Wlisses Henrique Veloso, Dejani Naiara Naiana, de Sousa Fernandes Matheus Santos, Yagin Fatma Hilal, Al-Hashem Fahaid, Elkholi Safaa M, Alyami Hanan, Souto Fabrício Oliveira
Keizo Asami Institute (iLIKA), Federal University of Pernambuco (UFPE), Recife, Pernambuco, Brazil.
Molecular Biology Laboratory (LABIMOL), Medical Sciences Center, Federal University of Paraíba (CCM/UFPB), João Pessoa, Paraíba, Brazil.
Front Immunol. 2024 Aug 30;15:1416715. doi: 10.3389/fimmu.2024.1416715. eCollection 2024.
This study was performed to identify predictive markers of worse outcomes in patients with severe COVID-19 in an intensive care unit.
Sixty patients with severe COVID-19, hospitalized in the Intensive Care Unit (ICU) between March and July 2021, were stratified into two groups according to the outcome survivors and non-survivors. After admission to the ICU, blood samples were collected directly for biomarker analysis. Routine hematological and biochemical biomarkers, as well as serum levels of cytokines, chemokines, and immunoglobulins, were investigated.
Lymphopenia, neutrophilia, and thrombocytopenia were more pronounced in non-surviving patients, while the levels of CRP, AST, creatinine, ferritin, AST, troponin I, urea, magnesium, and potassium were higher in the non-surviving group than the survival group. In addition, serum levels of IL-10, CCL2, CXCL9, and CXCL10 were significantly increased in patients who did not survive. These changes in the biomarkers evaluated were associated with increased mortality in patients with severe COVID-19.
The present study confirmed and expanded the validity of laboratory biomarkers as indicators of mortality in severe COVID-19.
本研究旨在确定重症监护病房中重症新型冠状病毒肺炎（COVID-19）患者预后较差的预测标志物。
2021年3月至7月期间在重症监护病房（ICU）住院的60例重症COVID-19患者，根据预后分为生存者和非生存者两组。入住ICU后，直接采集血样进行生物标志物分析。研究了常规血液学和生化生物标志物，以及细胞因子、趋化因子和免疫球蛋白的血清水平。
非生存患者的淋巴细胞减少、中性粒细胞增多和血小板减少更为明显，而非生存组的CRP、AST、肌酐、铁蛋白、AST、肌钙蛋白I、尿素、镁和钾水平高于生存组。此外，未存活患者的血清IL-10、CCL2、CXCL9和CXCL10水平显著升高。所评估的生物标志物的这些变化与重症COVID-19患者死亡率增加相关。
本研究证实并扩展了实验室生物标志物作为重症COVID-19死亡率指标的有效性。
